IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 13.1 SEK 8.26% Market Closed
Market Cap: 678.4m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IRLAB Therapeutics AB
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Total Liabilities & Equity
kr177.1m
CAGR 3-Years
-22%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Total Liabilities & Equity
kr1.7B
CAGR 3-Years
14%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Total Liabilities & Equity
kr3.6B
CAGR 3-Years
51%
CAGR 5-Years
45%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Total Liabilities & Equity
kr10B
CAGR 3-Years
56%
CAGR 5-Years
136%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Total Liabilities & Equity
kr634.7m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Total Liabilities & Equity
kr4.3B
CAGR 3-Years
109%
CAGR 5-Years
105%
CAGR 10-Years
N/A
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
679.5m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
16.06 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is IRLAB Therapeutics AB's Total Liabilities & Equity?
Total Liabilities & Equity
177.1m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Total Liabilities & Equity amounts to 177.1m SEK.

What is IRLAB Therapeutics AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-5%

Over the last year, the Total Liabilities & Equity growth was -45%. The average annual Total Liabilities & Equity growth rates for IRLAB Therapeutics AB have been -22% over the past three years , -5% over the past five years .

Back to Top